BioCentury | Dec 4, 2018
Distillery Therapeutics

Cancer

...Minnelide in Phase II testing for pancreatic cancer and Phase I testing for gastrointestinal cancer. Chaperone Technologies Inc....
BioCentury | May 30, 2018
Distillery Therapeutics

Cancer

...inhibitor, in Phase II testing for pancreatic cancer and Phase I testing for gastrointestinal cancer. Chaperone Technologies Inc....
BioCentury | Jan 4, 2010
Finance

Restructuring watch

Restructuring watch Date Company Staff cuts Cash Years cash pre-cut Cash date Oper loss for 9 mos ended 9/30 10/28/09 SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) 17% to 34 $34.6 2.60 9/30/09 $10.0 Cuts primarily in R&D;...
BioCentury | Dec 14, 2009
Company News

Chaperone Technologies, MerLion deal

...fluoroquinolone antibacterial in Phase II testing to treat bacterial infections. Further terms were not disclosed. Chaperone Technologies Inc....
BioCentury | Nov 2, 2009
Company News

Amicus Therapeutics, Shire deal

The companies mutually ended a 2007 deal to develop Amicus' Amigal migalastat, Plicera afegostat tartrate and AT2220 deoxynojirimycin. Amicus regains all rights to the compounds and will receive a final $5.2 million payment from the...
BioCentury | Oct 30, 2009
Company News

Amicus, Shire end deal

Amicus Therapeutics Inc. (NASDAQ:FOLD) said late Thursday that it and Shire plc (LSE:SHP; NASDAQ:SHPGY) mutually ended a 2007 deal to develop Amicus' Amigal migalastat, Plicera afegostat tartrate and AT2220 deoxynojirimycin. Amicus regains all rights to...
Items per page:
1 - 6 of 6
BioCentury | Dec 4, 2018
Distillery Therapeutics

Cancer

...Minnelide in Phase II testing for pancreatic cancer and Phase I testing for gastrointestinal cancer. Chaperone Technologies Inc....
BioCentury | May 30, 2018
Distillery Therapeutics

Cancer

...inhibitor, in Phase II testing for pancreatic cancer and Phase I testing for gastrointestinal cancer. Chaperone Technologies Inc....
BioCentury | Jan 4, 2010
Finance

Restructuring watch

Restructuring watch Date Company Staff cuts Cash Years cash pre-cut Cash date Oper loss for 9 mos ended 9/30 10/28/09 SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) 17% to 34 $34.6 2.60 9/30/09 $10.0 Cuts primarily in R&D;...
BioCentury | Dec 14, 2009
Company News

Chaperone Technologies, MerLion deal

...fluoroquinolone antibacterial in Phase II testing to treat bacterial infections. Further terms were not disclosed. Chaperone Technologies Inc....
BioCentury | Nov 2, 2009
Company News

Amicus Therapeutics, Shire deal

The companies mutually ended a 2007 deal to develop Amicus' Amigal migalastat, Plicera afegostat tartrate and AT2220 deoxynojirimycin. Amicus regains all rights to the compounds and will receive a final $5.2 million payment from the...
BioCentury | Oct 30, 2009
Company News

Amicus, Shire end deal

Amicus Therapeutics Inc. (NASDAQ:FOLD) said late Thursday that it and Shire plc (LSE:SHP; NASDAQ:SHPGY) mutually ended a 2007 deal to develop Amicus' Amigal migalastat, Plicera afegostat tartrate and AT2220 deoxynojirimycin. Amicus regains all rights to...
Items per page:
1 - 6 of 6